MedImmune, Inc. (Nasdaq: MEDI) announced today that it has begun dosing lupus patients in a Phase 1 clinical trial to evaluate the safety and tolerability of MEDI-545, its monoclonal antibody (MAb) targeting interferon-alpha. The MAb is being developed for the
